Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

CONCLUSION: The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).
PMID: 29405274 [PubMed - in process]

Source: The British Journal of Surgery - February 1, 2018 Category: Surgery Authors: Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M, Bile Duct Cancer Adjuvant Trial (BCAT) Study Group Tags: Br J Surg Source Type: research